A Study of HQK-1001 in Patients With Sickle Cell Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of three dose levels of
HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.